News | Heart Failure | March 25, 2024

UMass Amherst Engineers Create Bioelectronic Mesh Capable of Growing with Cardiac Tissues for Comprehensive Heart Monitoring

In a boon for medical researchers, new tool is the first that can measure both mechanical movement and electrical signal in vitro using a single sensor

A bioelectronic mesh, studded with graphene sensors (red), can measure the electrical signal and movement  of cardiac tissue (purple and green) at the same time.

March 25, 2024 — A team of engineers led by the University of Massachusetts Amherst and including colleagues from the Massachusetts Institute of Technology (MIT) recently announced in the journal Nature Communications that they had successfully built a tissue-like bioelectronic mesh system integrated with an array of atom-thin graphene sensors that can simultaneously measure both the electrical signal and the physical movement of cells in lab-grown human cardiac tissue. In a research first, this tissue-like mesh can grow along with the cardiac cells, allowing researchers to observe how the heart’s mechanical and electrical functions change during the developmental process. The new device is a boon for those studying cardiac disease as well as those studying the potentially toxic side-effects of many common drug therapies.

Cardiac disease is the leading cause of human morbidity and mortality across the world. The heart is also very sensitive to therapeutic drugs, and the pharmaceutical industry spends millions of dollars in testing to make sure that its products are safe. However, ways to effectively monitor living cardiac tissue are extremely limited.

In part, this is because it is very risky to implant sensors in a living heart, but also because the heart is a complex kind of muscle with more than one thing that needs monitoring. “Cardiac tissue is very special,” says Jun Yao, associate professor of electrical and computer engineering in UMass Amherst’s College of Engineering and the paper’s senior author. “It has a mechanical activity—the contractions and relaxations that pump blood through our body—coupled to an electrical signal that controls that activity.”

But today’s sensors can typically only measure one characteristic at a time, and a two-sensor device that could measure both charge and movement would be so bulky as to impede the cardiac tissue’s function. Until now, there was no single sensor capable of measuring the heart’s dual properties without interfering with its functioning.

The new device is built of two critical components, explains lead author Hongyan Gao, who is pursuing his Ph.D. in electrical engineering at UMass Amherst. The first is a three-dimensional cardiac microtissue (CMT), grown in a lab from human stem cells under the guidance of co-author Yubing Sun, associate professor of mechanical and industrial engineering at UMass Amherst. CMT has become the preferred model for in vitro testing because it is the closest analog yet to a full-size, living human heart. However, because CMT is grown in a test tube, it has to mature, a process that takes time and can be easily disrupted by a clumsy sensor.

The second critical component involves graphene—a pure-carbon substance only one atom thick. Graphene has a few surprising quirks to its nature that make it perfect for a cardiac sensor. Graphene is electrically conductive, and so it can sense the electrical charges shooting through cardiac tissue. It is also piezoresistive, which means that as it is stretched—say, by the beating of a heart—its electrical resistance increases. And because graphene is impossibly thin, it can register even the tiniest flutter of muscle contraction or relaxation and can do so without impeding the heart’s function, all through the maturation process. Co-author Jing Kong, professor of electrical engineering at MIT, and her group supplied this critical graphene material.

“Although there have already been many applications for graphene, it is wonderful to see that it can be used in this critical need, which takes advantage of graphene’s different characteristics,” says Kong.

Gao, Yao and their colleagues then embedded a series of graphene sensors in a soft, stretchable porous mesh scaffold they developed that has close structural and mechanical properties to human tissue and which can be applied non-invasively to cardiac tissue.

 “No one has ever done this before,” says Gao. “Graphene can survive in a biological environment without degrading for a very long time and not lose its conductivity, so we can monitor the CMT across its entire maturation process.”

“This is crucial for a number of reasons,” adds Yao. “Our sensor can give real-time feedback to scientists and drug researchers, and it can do so in a cost-effective way. We take pride in using the insights of electrical engineering to help build tools that can be useful to a wide range of researchers.”

In the future, Gao says, he hopes to be able to adapt his sensor to grander scales, even to in vivo monitoring, which would provide the best-possible data to help solve cardiac disease.

This research was supported by the Army Research Office, the National Institutes of Health, the U.S. National Science Foundation, the Semiconductor Research Corporation, and the Link Foundation, as well as the Institute for Applied Life Sciences at UMass Amherst.

For more information: https://www.umass.edu/


Related Content

News | Heart Failure

March 24, 2026 — New research shows that small improvements to sleep, diet quality and physical activity, made in ...

Home March 25, 2026
Home
News | Heart Failure

March 16, 2026 — Cytokinetics has announced four presentations related to Myqorzo (aficamten) at the American College of ...

Home March 16, 2026
Home
Feature | Heart Failure | Rohit Sood, MD, PhD

Cardiovascular disease (CVD) is a serious global health burden that encompasses a broad group of diseases that affect ...

Home February 12, 2026
Home
News | Heart Failure

Feb. 3, 2026 — Bristol Myers Squibb has launched "Change the Target. Change What’s Possible," an educational campaign ...

Home February 03, 2026
Home
News | Heart Failure

Jan. 27, 2026 — A new national study reveals a stark disconnect between Americans’ desire for preventive cardiac ...

Home January 27, 2026
Home
News | Heart Failure

Jan. 6, 2026 — Millions of Americans living with heart failure are not receiving medications that have been proven for ...

Home January 10, 2026
Home
News | Heart Failure

Dec. 16,2025 — The European Society of Cardiology (ESC) has welcomed the adoption of the Safe Hearts Plan, a landmark ...

Home December 23, 2025
Home
News | Heart Failure

Dec. 18, 2025 — Heartflow, Inc., a provider of AI technology for coronary artery disease (CAD), has announced the ...

Home December 22, 2025
Home
News | Heart Failure

Dec. 18, 2025 – Ventric Health, a medtech company enabling early detection of heart failure (HF) in a primary care ...

Home December 18, 2025
Home
News | Heart Failure

Oct. 22, 2025 – Ventric Health, a medtech innovator enabling early detection of heart failure (HF) in a primary care ...

Home October 28, 2025
Home
Subscribe Now